NCT05077072

Brief Summary

This phase II trial compares different pain management interventions (standard of care \[SOC\], neurofeedback \[NFB\] training, and compassionate high alert team \[CHAT\]) in patients diagnosed with head and neck cancer who are at risk of developing non-medical opioid use (NMOU). The current standard treatment includes regular clinic visits and supportive care and counseling (including topics like patient-doctor communication, cancer care goals, financial issues counseling, and other topics). NFB training is a type of therapy that uses an electroencephalograph (EEG) and a computer software program to measure brain wave activity. The goal of NFB is to help teach patients with pain how to change their own brain waves to lower their feelings of pain and help improve their quality of life. CHAT is a supportive care intervention that includes symptom and pain management, counseling (about pain, symptoms, opioid use and safety, stress, and quality of life), and support for patients and their family members. NFB and CHAT may help to manage pain and lower patient use of opioids.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for phase_2

Timeline
18mo left

Started Oct 2021

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress76%
Oct 2021Oct 2027

First Submitted

Initial submission to the registry

September 22, 2021

Completed
16 days until next milestone

Study Start

First participant enrolled

October 8, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 13, 2021

Completed
6.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2027

Last Updated

May 4, 2026

Status Verified

April 1, 2026

Enrollment Period

6.1 years

First QC Date

September 22, 2021

Last Update Submit

April 28, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Frequency of non-medical opioid use (NMOU) behaviors

    Composite NMOU score is calculated by summing the number of times each behavior suggestive of NMOU is recorded.

    through study completion, an average of a year.

Study Arms (3)

ARM I (CHAT)

EXPERIMENTAL

Patients participate in CHAT counseling intervention over 45-60 minutes twice a month for up to 12 weeks.

Other: CounselingOther: Questionnaire Administration

ARM II (NFB)

EXPERIMENTAL

Patients undergo NFB intervention over 20-30 minutes twice a week for up to 10 weeks.

Procedure: ElectroencephalographyBehavioral: NeurofeedbackOther: Questionnaire Administration

ARM III (SOC)

ACTIVE COMPARATOR

Patients receive 2-3 standard of care sessions per month over 45-60 minutes for up to 12 weeks.

Other: Best PracticeOther: Questionnaire Administration

Interventions

Receive SOC

Also known as: standard of care, standard therapy
ARM III (SOC)

Participate in CHAT counseling intervention

Also known as: Counseling Intervention
ARM I (CHAT)

Undergo EEG

Also known as: EEG, electroencephalogram
ARM II (NFB)
NeurofeedbackBEHAVIORAL

Undergo NFB intervention

Also known as: EEG biofeedback
ARM II (NFB)

Ancillary studies

ARM I (CHAT)ARM II (NFB)ARM III (SOC)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of HNC, with patient scheduled to receive radiation therapy, with or without evidence of active disease
  • Willingness to be seen in the outpatient supportive care center (SCC)
  • History of use of non-medical opioid use (Screener and Opioid Assessment for Patients with Pain \[SOAPP\] \>= 7+ and/or Cut Down, Annoyed, Guilty, and Eye opener questionnaire \[CAGE\] \>= 2+)
  • Physician-estimated prognosis of at least 12 months
  • Age 18 or older
  • Able to complete study assessments
  • Willing to sign written informed consent
  • Both human papillomavirus (HPV) and non-HPV patients will be included
  • Patients currently receiving opioids for at least 1 week
  • Able to read, write and speak English

You may not qualify if:

  • Individual with clinically evident impaired cognition by Memorial Delirium Assessment Scale (MDAS) score of \>= 13
  • Employees of MD Anderson Cancer Center

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

M D Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

MeSH Terms

Interventions

Practice Guidelines as TopicStandard of CareCounselingNeurofeedback

Intervention Hierarchy (Ancestors)

Guidelines as TopicQuality Assurance, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and EvaluationQuality Indicators, Health CareMental Health ServicesBehavioral Disciplines and ActivitiesCommunity Health ServicesHealth ServicesHealth Care Facilities Workforce and ServicesBiofeedback, PsychologyMind-Body TherapiesComplementary TherapiesTherapeuticsBehavior TherapyPsychotherapyFeedback, Psychological

Study Officials

  • Sriram Yennu

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 22, 2021

First Posted

October 13, 2021

Study Start

October 8, 2021

Primary Completion (Estimated)

October 31, 2027

Study Completion (Estimated)

October 31, 2027

Last Updated

May 4, 2026

Record last verified: 2026-04

Locations